MGI announced its collaboration with Prepaire Labs at MEDLAB Middle East 2024 to further empower precision medicine. The collaboration, includes MGI's first corporate order of the revolutionary DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in the Middle East and the first application of the company's sequencing technology in drug discovery in the region. Powered by MGI's proprietary DNBSEQTM technology, T20 is a fully automated genetic sequencer that has achieved major technological breakthroughs and made waves in the global industry for lowering genome sequencing cost to sub-$100 per genome.

Designed to meet the most challenging sequencing scenarios, it covers all high-throughput sequencing needs in scientific research and clinical applications, including WGS, WGBS, stLFR, single-cell sequencing, Stereo-seq and more. MGI and Prepaire Labs will focus on: Developing assays for whole genome sequencing. Creating a 100% automated smart laboratory.

Innovating sequencing methods for complex genome analysis. Co-marketing to enhance scientific collaboration. MGI's DNBSEQ-T20×2, along with other products including the ZOID-ILR Laboratory Robot, DNBSEQTM platforms, automated sample preparation systems, and ultra-low-temperature biorepository solutions, will be on exhibit at MEDLAB Middle East 2024.

Attendees are welcome to visit MGI's booth #Z4.H10 in Dubai World Trade Centre between 5 and 8 February.